Octagon Capital Advisors
Overview
Octagon Capital Advisors is a hedge fund manager that invests in public and private healthcare companies globally.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Numab Therapeutics | Jan 2025 | Series C Extension | - |
| Shanghai Hanyu Medical Technology | Mar 2021 | Series D Extension | Co-investor |
| Aktis Oncology | Aug 2022 | Series A Extension | - |
| NiKang Therapeutics | May 2021 | Series C | Lead |
| Sonoma Biotherapeutics | Aug 2021 | Series B | - |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Octagon Capital Advisors based?
Octagon Capital Advisors is headquartered in New York City, New York, United States.
When was Octagon Capital Advisors founded?
Octagon Capital Advisors was founded in 2019.
How many portfolio companies does Octagon Capital Advisors have?
Octagon Capital Advisors has 6 portfolio companies in Caplight's dataset.
What are some companies in Octagon Capital Advisors's portfolio?
Portfolio companies visible on Caplight include Numab Therapeutics, Shanghai Hanyu Medical Technology, Aktis Oncology, NiKang Therapeutics, Sonoma Biotherapeutics.
What was Octagon Capital Advisors's most recent investment shown here?
Octagon Capital Advisors's most recent investment in this portfolio sample was in Numab Therapeutics in 2025.
What sectors does Octagon Capital Advisors focus on?
Octagon Capital Advisors focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Octagon Capital Advisors focus on?
Octagon Capital Advisors typically invests at the Mid stage.
What is Octagon Capital Advisors's AUM?
Octagon Capital Advisors's assets under management are estimated between $919.8M and $919.8M.